Deutsche Bank AG upgraded shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) from a hold rating to a buy rating in a research note published on Tuesday morning. They currently have $128.00 price objective on the medical equipment provider’s stock.

Several other equities analysts also recently weighed in on the company. Jefferies Group LLC reissued a buy rating and set a $136.00 target price on shares of Zimmer Biomet Holdings in a research report on Friday, November 3rd. Stifel Nicolaus reissued a hold rating and set a $120.00 target price on shares of Zimmer Biomet Holdings in a research report on Friday, November 3rd. Gabelli initiated coverage on Zimmer Biomet Holdings in a research report on Thursday, August 24th. They set a buy rating and a $142.00 target price on the stock. Zacks Investment Research downgraded Zimmer Biomet Holdings from a hold rating to a strong sell rating in a research report on Tuesday, August 8th. Finally, SunTrust Banks, Inc. reissued a buy rating and set a $136.00 target price on shares of Zimmer Biomet Holdings in a research report on Monday, October 2nd. Four analysts have rated the stock with a sell rating, seven have issued a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Zimmer Biomet Holdings presently has an average rating of Hold and an average target price of $133.71.

Zimmer Biomet Holdings (ZBH) traded up $1.15 during trading hours on Tuesday, reaching $112.21. The company’s stock had a trading volume of 1,308,200 shares, compared to its average volume of 1,365,892. The company has a current ratio of 1.47, a quick ratio of 0.78 and a debt-to-equity ratio of 0.88. Zimmer Biomet Holdings has a 1-year low of $98.20 and a 1-year high of $133.49. The company has a market cap of $22,720.00, a P/E ratio of 13.76, a price-to-earnings-growth ratio of 1.72 and a beta of 1.17.

Zimmer Biomet Holdings (NYSE:ZBH) last released its quarterly earnings data on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.74 by ($0.02). Zimmer Biomet Holdings had a return on equity of 16.29% and a net margin of 8.36%. The firm had revenue of $1.82 billion during the quarter, compared to the consensus estimate of $1.83 billion. During the same period in the previous year, the firm earned $1.79 EPS. The business’s revenue was down .8% compared to the same quarter last year. equities research analysts expect that Zimmer Biomet Holdings will post 8.03 EPS for the current fiscal year.

WARNING: This news story was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another publication, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/11/15/zimmer-biomet-holdings-inc-zbh-upgraded-to-buy-by-deutsche-bank-ag.html.

A number of large investors have recently made changes to their positions in the stock. Enterprise Financial Services Corp increased its position in Zimmer Biomet Holdings by 0.3% during the 2nd quarter. Enterprise Financial Services Corp now owns 2,646 shares of the medical equipment provider’s stock valued at $340,000 after buying an additional 9 shares in the last quarter. Parkside Financial Bank & Trust increased its holdings in shares of Zimmer Biomet Holdings by 3.9% in the second quarter. Parkside Financial Bank & Trust now owns 872 shares of the medical equipment provider’s stock valued at $112,000 after purchasing an additional 33 shares during the period. CWA Asset Management Group LLC increased its holdings in shares of Zimmer Biomet Holdings by 1.8% in the second quarter. CWA Asset Management Group LLC now owns 1,952 shares of the medical equipment provider’s stock valued at $251,000 after purchasing an additional 34 shares during the period. Advisory Services Network LLC increased its holdings in shares of Zimmer Biomet Holdings by 1.0% in the second quarter. Advisory Services Network LLC now owns 3,690 shares of the medical equipment provider’s stock valued at $474,000 after purchasing an additional 37 shares during the period. Finally, Palladium Partners LLC increased its holdings in shares of Zimmer Biomet Holdings by 1.7% in the second quarter. Palladium Partners LLC now owns 2,501 shares of the medical equipment provider’s stock valued at $321,000 after purchasing an additional 41 shares during the period. 85.44% of the stock is currently owned by institutional investors.

Zimmer Biomet Holdings Company Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Analyst Recommendations for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Stock Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related stocks with our FREE daily email newsletter.